Chemotherapy with bevacizumab for metastatic colorectal cancer: a retrospective review of 181 Japanese patients
International Journal of Clinical Oncology, 06/12/2012
Saito S et al. – Although the survival benefit of bevacizumab in Japanese patients with metastatic colorectal cancer (mCRC) was similar to that observed in previous clinical trials, this study showed a high incidence of gastrointestinal (GI) perforation in comparison to previous studies. Therefore, the careful selection of patients with few risk factors for this complication is likely to lead to a greater benefit from bevacizumab treatment.